Pay in 4 interest-free payments of $5.64 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Joint Bone Spine
GLP-1 medications can be powerful tools for weight management and metabolic health
In fact, it is tirzepatide, a newer medication in the same family.Jan 08, 2026 9:52 AM EST With files from Jennifer La Grassa and Melanie Glanz
Exenatide extended-release (Bydureon, Bydureon BCise) received FDA approval in 2012, offering once-weekly subcutaneous administration
You also need to have tried everything else and be unable to join a clinical trial
Snapshot of the 2026 Speaker Faculty Top Takeaways: Unlocked the next generation of GLP-1 combinations and gained competitive intelligence on multi-agonist and combination therapies designed to enhance efficacy, minimize muscle loss, and improve body composition for superior patient outcomes Discovered high-value indication expansion and explored the next frontier of GLP-1 development beyond obesity through exclusive data on clinical programs targeting liver, renal and cardiometabolic disorders alongside neurological diseases and womens health conditions Mastered alternative delivery and patient adherence through dedicated sessions focused on overcoming the challenges of administration through oral programs and less frequent dosing strategies for long-term patient success Benchmarked against industry titans and innovators and heard directly from the companies leading the pipeline, including experts from Eli Lilly , Constructive Bio and Regeneron
